Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus DEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 250 50 versus DEXACORT.
ADVAIR DISKUS 250/50 vs DEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators. Salmeterol xinafoate is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
1 inhalation (fluticasone propionate 250 mcg and salmeterol 50 mcg) twice daily, approximately 12 hours apart, via oral inhalation.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
None Documented
None Documented
Fluticasone propionate: 14-17 hours (terminal). Salmeterol: 5.5 hours (terminal). The fluticasone half-life supports twice-daily dosing with potential accumulation.
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Fluticasone propionate: <5% renal (as metabolites), majority biliary/fecal. Salmeterol: 57% renal (as metabolites), 30% fecal.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid